{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:16:57Z","timestamp":1790817417735,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00417-021-05190-4","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T03:41:08Z","timestamp":1628134868000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term outcomes of polypoidal choroidal vasculopathy in comparison with typical exudative age-related macular degeneration"],"prefix":"10.1007","volume":"260","author":[{"given":"Hyeon Cheol","family":"Roh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-3465","authenticated-orcid":false,"given":"Se Woong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Soo","family":"Eun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Jun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"5190_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","volume":"291","author":"NM Bressler","year":"2004","unstructured":"Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291:1900\u20131901","journal-title":"JAMA"},{"key":"5190_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","volume":"115","author":"TY Wong","year":"2008","unstructured":"Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I (2008) The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115:116\u2013126","journal-title":"Ophthalmology"},{"key":"5190_CR3","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606\u20132617","journal-title":"N Engl J Med"},{"key":"5190_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.survophthal.2010.03.004","volume":"55","author":"Y Imamura","year":"2010","unstructured":"Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA (2010) Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 55:501\u2013515","journal-title":"Surv Ophthalmol"},{"key":"5190_CR5","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379:1728\u20131738","journal-title":"Lancet"},{"key":"5190_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, Wong TY, Aung T (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29:19\u201329","journal-title":"Prog Retin Eye Res"},{"issue":"309\u2013318","key":"5190_CR7","first-page":"e302","volume":"158","author":"G Coscas","year":"2014","unstructured":"Coscas G, Yamashiro K, Coscas F, De Benedetto U, Tsujikawa A, Miyake M, Gemmy Cheung CM, Wong TY, Yoshimura N (2014) Comparison of exudative age-related macular degeneration subtypes in Japanese and French Patients: multicenter diagnosis with multimodal imaging. Am J Ophthalmol 158(309\u2013318):e302","journal-title":"Am J Ophthalmol"},{"key":"5190_CR8","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388-1398","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"5190_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","volume":"156","author":"A Oishi","year":"2013","unstructured":"Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, Kita M, Nagai T, Fujihara M, Bessho N, Uenishi M, Kurimoto Y, Negi A (2013) Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 156:644\u2013651","journal-title":"Am J Ophthalmol"},{"key":"5190_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, Cheung GCM, Zhang Z, Leal S, Ishibashi T, Investigators PLANET (2018) Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol 136:786\u2013793","journal-title":"JAMA Ophthalmol"},{"key":"5190_CR11","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292\u20132299","journal-title":"Ophthalmology"},{"key":"5190_CR12","doi-asserted-by":"crossref","unstructured":"Miyata M, Ooto S, Yamashiro K, Tamura H, Hata M, Ueda-Arakawa N, Yoshikawa M, Numa S, Tsujikawa A (2018) Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. Br J Ophthalmol","DOI":"10.1136\/bjophthalmol-2018-311963"},{"key":"5190_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/bjophthalmol-2017-310448","volume":"102","author":"T Hikichi","year":"2018","unstructured":"Hikichi T (2018) Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy. Br J Ophthalmol 102:97\u2013101","journal-title":"Br J Ophthalmol"},{"key":"5190_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0002-9394(99)00253-6","volume":"129","author":"H Iijima","year":"2000","unstructured":"Iijima H, Iida T, Imai M, Gohdo T, Tsukahara S (2000) Optical coherence tomography of orange-red subretinal lesions in eyes with idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 129:21\u201326","journal-title":"Am J Ophthalmol"},{"key":"5190_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","volume":"125","author":"SD Adrean","year":"2018","unstructured":"Adrean SD, Chaili S, Ramkumar H, Pirouz A, Grant S (2018) Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol. Ophthalmology 125:1047\u20131053","journal-title":"Ophthalmology"},{"key":"5190_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ (2010) Novel method for analyzing snellen visual acuity measurements. Retina 30:1046\u20131050","journal-title":"Retina"},{"key":"5190_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/IAE.0000000000001556","volume":"38","author":"L Yeung","year":"2018","unstructured":"Yeung L, Kuo CN, Chao AN, Chen KJ, Wu WC, Lai CH, Wang NK, Hwang YS, Chen CL, Lai CC (2018) Angiographic subtypes of polypoidal choroidal vasculopathy in Taiwan: a prospective multicenter study. Retina 38:263\u2013271","journal-title":"Retina"},{"key":"5190_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3928\/15428877-20091030-07","volume":"40","author":"YC Chang","year":"2009","unstructured":"Chang YC, Wu WC (2009) Polypoidal choroidal vasculopathy in Taiwanese patients. Ophthalmic Surg Lasers Imaging 40:576\u2013581","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"5190_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ajo.2010.05.035","volume":"150","author":"AN Stangos","year":"2010","unstructured":"Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP (2010) Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 150:666\u2013673","journal-title":"Am J Ophthalmol"},{"key":"5190_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/bjo.2008.150029","volume":"94","author":"GT Kokame","year":"2010","unstructured":"Kokame GT, Yeung L, Lai JC (2010) Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 94:297\u2013301","journal-title":"Br J Ophthalmol"},{"key":"5190_CR21","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","volume":"111","author":"WM Chan","year":"2004","unstructured":"Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH (2004) Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 111:1576\u20131584","journal-title":"Ophthalmology"},{"key":"5190_CR22","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK, EVEREST II study group (2017) Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol 135:1206\u20131213","journal-title":"JAMA Ophthalmol"},{"key":"5190_CR23","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.ophtha.2013.03.016","volume":"120","author":"K Tozer","year":"2013","unstructured":"Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB, Russell SR, Boldt HC, Sohn EH (2013) Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology 120:2029\u20132034","journal-title":"Ophthalmology"},{"key":"5190_CR24","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.2147\/OPTH.S218378","volume":"13","author":"F Horner","year":"2019","unstructured":"Horner F, Lip PL, Clark H, Chavan R, Sarmad A, Mushtaq B (2019) Real-world visual and clinical outcomes for patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: an 8-year observational cohort (AMD8). Clin Ophthalmol 13:2461\u20132467","journal-title":"Clin Ophthalmol"},{"key":"5190_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","volume":"156","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ (2013) Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol 156:652\u2013660","journal-title":"Am J Ophthalmol"},{"key":"5190_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/jop.2015.0073","volume":"32","author":"YS Chang","year":"2016","unstructured":"Chang YS, Kim JH, Kim KM, Kim JW, Lee TG, Kim CG, Cho SW (2016) Long-term outcomes of anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther 32:219\u2013224","journal-title":"J Ocul Pharmacol Ther"},{"key":"5190_CR27","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.2147\/OPTH.S172115","volume":"12","author":"K Azuma","year":"2018","unstructured":"Azuma K, Asaoka R, Matsuda A, Lee J, Shimizu K, Inui H, Murata H, Ogawa A, Yamamoto M, Inoue T, Obata R (2018) Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients. Clin Ophthalmol 12:1589\u20131597","journal-title":"Clin Ophthalmol"},{"key":"5190_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00417-014-2688-1","volume":"253","author":"M Hata","year":"2015","unstructured":"Hata M, Tsujikawa A, Miyake M, Yamashiro K, Ooto S, Oishi A, Nakanishi H, Takahashi A, Yoshimura N (2015) Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 253:221\u2013227","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5190_CR29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF, CATT Research Group (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121:150\u2013161","journal-title":"Ophthalmology"},{"key":"5190_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12886-017-0544-x","volume":"17","author":"L Gonzalez-Buendia","year":"2017","unstructured":"Gonzalez-Buendia L, Delgado-Tirado S, Sanabria MR, Fernandez I, Coco RM (2017) Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab. BMC Ophthalmol 17:147","journal-title":"BMC Ophthalmol"},{"issue":"94\u2013103","key":"5190_CR31","first-page":"e101","volume":"161","author":"Y Kuroda","year":"2016","unstructured":"Kuroda Y, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Oishi A, Nakanishi H, Miyake M, Yoshikawa M, Yoshimura N (2016) Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab treatment. Am J Ophthalmol 161(94\u2013103):e101","journal-title":"Am J Ophthalmol"},{"key":"5190_CR32","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, McAllister IL, Essex RW, Morlet N, Hunyor AP, Fight Retinal Blindness Study Group (2015) Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology 122:1837\u20131845","journal-title":"Ophthalmology"},{"key":"5190_CR33","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","volume":"121","author":"C Simader","year":"2014","unstructured":"Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM (2014) Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 121:1237\u20131245","journal-title":"Ophthalmology"},{"key":"5190_CR34","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/IAE.0000000000001282","volume":"37","author":"WM Haddad","year":"2017","unstructured":"Haddad WM, Minous FL, Legeai J, Souied EH (2017) Long-term outcomes and incidence of recurrence of neovascularization in treated exudative age-related macular degeneration. Retina 37:951\u2013961","journal-title":"Retina"},{"key":"5190_CR35","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/IAE.0000000000002668","volume":"40","author":"MR Starr","year":"2020","unstructured":"Starr MR, Kung FF, Mejia CA, Bui YT, Bakri SJ (2020) Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. Retina 40:1665\u20131672","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05190-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05190-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05190-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T14:24:34Z","timestamp":1642515874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05190-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5190"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05190-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"23 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement of obtaining informed consent was waived due to the retrospective nature of this study. This study was approved by the Institutional Review Board of Samsung Medical Center (No. 2020\u201309-066).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}